ReviewFrontiers in cardiovascular medicine2026
Engineered bacteria: a novel era for metabolic, cardiovascular and cerebrovascular diseases therapy.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are a large number of people suffer from metabolic, cardiovascular, and cerebrovascular diseases, posing a significant threat to public health. Previous studies have suggested that cardiovascular and cerebrovascular diseases are frequently accompanied by changes in intestinal flora and metabolites, which play a crucial role in the progression of metabolic, cardiovascular and cerebrovascular diseases. Engineered bacteria, as a tool for efficiently expressing foreign genes within a bacterial cell line, has attracted considerable attention for cancer treatment over the past decades. In recent years, engineered bacteria has been extended to metabolic disorders, cardiovascular and cerebrovascular diseases therapy and has been a promising tool. However, several challenges persist, including the necessity of more refined strain selection and design. Furthermore, there is no relevant review on the application of engineering bacteria in the fields of metabolic diseases and cardiovascular diseases currently. Therefore, this review is aimed to explore the alterations of intestinal microbiota and metabolome associated with metabolic and cardio-cerebrovascular diseases, as well as the potential application of engineered bacteria in treating these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.